ACRIVON THERAPEUTICS INC's ticker is and the CUSIP is 004890109. A total of 40 filers reported holding ACRIVON THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $1,287,333 | -68.7% | 430,252 | 0.0% | 0.09% | -73.0% |
| Q3 2023 | $4,113,209 | -34.1% | 430,252 | -10.7% | 0.32% | -33.3% |
| Q2 2023 | $6,242,534 | +27.7% | 481,677 | 0.0% | 0.48% | +41.1% |
| Q1 2023 | $4,889,985 | +10.2% | 481,677 | 0.0% | 0.34% | +35.7% |
| Q4 2022 | $4,439,135 | – | 481,677 | – | 0.25% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sands Capital Ventures, LLC | 1,652,605 | $21,417,761 | 6.34% |
| RA Capital Management | 4,810,508 | $62,344,184 | 1.18% |
| Perceptive Advisors | 3,007,858 | $38,981,840 | 1.13% |
| NEA Management Company, LLC | 481,677 | $6,242,534 | 0.48% |
| DAFNA Capital Management LLC | 76,852 | $996,002 | 0.27% |
| AAF Wealth Management, LLC | 10,678 | $138,387 | 0.09% |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 100,000 | $1,296,000 | 0.03% |
| MARSHALL WACE, LLP | 597,469 | $7,743,198 | 0.02% |
| FEDERATED HERMES, INC. | 304,411 | $3,945,167 | 0.01% |
| Citadel Advisors | 1,649,646 | $21,379,412 | 0.00% |